. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2014 Dec 27;15(4):214–221.e1. doi: 10.1016/j.clml.2014.12.008

Table 1.

Baseline Body Weight, Body Mass Index, Total Cholesterol, and Albumin

Characteristic	Ruxolitinib (n = 155)	Placebo (n = 154)
Mean (SD) body weight, kg	72.2 (16.2)	72.2 (13.7)
Mean BMI (SD), kg/m²	25.1 (5.0)	24.8 (4.0)
BMI < 22 kg/m², % of patients	23	28
Mean (SD) total cholesterol, mg/dL	117.3 (34.5)	114.3 (35.6)
Total cholesterol < 150 mg/dL, % of patients	82	82
Mean (SD) LDL-C, mg/dL	55.4 (26.2)	53.8 (26.5)
Mean (SD) HDL-C, mg/dL	29.3 (10.9)	29.1 (10.7)
Mean (SD) albumin, g/L	42.8 (3.7)	41.8 (4.1)

There were no significant differences in baseline characteristics between treatment groups with the exception of albumin (P < .05). P values were calculated using the t test for continuous variables and the Chi-square test for categorical variables.

Abbreviations: BMI = body mass index; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; SD = standard deviation.